Pfizer grabs a solid endorsement from FDA insiders for their knockoff of Amgen’s flagship drug Epogen
Pfizer’s second attempt to win an FDA OK for Hospira’s biosimilar of Amgen’s fast-declining anemia drug, Epogen, is on course to a likely approval …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
